Netmedi launches a digital solution for immuno-oncology follow-up
Finnish health technology company Netmedi has developed an innovative digital platform, Kaiku® Health IO, for the follow-up of patients treated with immune checkpoint inhibitors. The solution is about to enter multi-center clinical validation phase and has already attracted significant interest among a number of leading oncology clinics. Kaiku® Health IO provides a solution for enhanced management of immune-related adverse events, supporting patients and the care team throughout treatment and follow-up. Netmedi will launch Kaiku® Health IO Early Access Program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 4th 2016.
Kaiku® Health IO monitors the patients' health status in real-time and collects structured information about the impact of immunotherapy. The solution enables the care team to treat patients more effectively according to their individual needs, and to react timely to any alarming signals during patients' treatment and recovery.
"Cancer immunotherapy has the potential to significantly extend the lives of many cancer patients, which underlines the importance of systematic patient follow-up", says Professor Paolo A. Ascierto, Director at National Tumor Institute Fondazione G. Pascale, Naples, Italy. "In addition, the adverse event profile of immunotherapy differs from conventional oncological treatments. These events can be better managed if they are detected and treated early on. Immunotherapy sets new requirements for patient follow-up". The institute headed by Professor Ascierto is one of the leading immunotherapy centers in the world and has extensive experience in treating patients with immune checkpoint inhibitors.
Kaiku® Health IO has been developed in co-operation with several Finnish and European oncology experts. "Netmedi is committed to supporting the treatment of cancer patients by developing easy-to-use, intelligent digital services for patient-centric follow-up", says the CEO of Netmedi Lauri Sippola.